First-in-class oral therapeutics for neurodegeneration
In collaboration with world-class institutions and industry leaders
200M+
Addressable Patients
10+
Years of R&D
3
Species Validated
The Global Burden
SBC003 starts here
Current Indications
Three retinal indications with no disease-modifying treatment, addressed by a single oral mechanism.
2M+ patients worldwide
Inherited retinal dystrophy causing progressive vision loss from childhood, leading to legal blindness. No approved disease-modifying treatment exists.
Read more →200M+ affected globally
The leading cause of irreversible vision loss in people over 50. Accounts for 85-90% of all AMD cases with no effective treatment available.
Read more →2M+ across major markets
Progressive optic nerve degeneration affecting retinal ganglion cells. Commonly secondary to glaucoma and diabetic retinopathy.
Read more →Next indication · CNS Neurodegeneration · In discovery
The neuroprotective mechanism extends beyond the retina, with preclinical discovery ongoing across Alzheimer's, Parkinson's, ALS, and Stroke.
An orally delivered lipid therapeutic that harnesses the neuroglobin pathway to halt and reverse neuronal loss; no injections required.
Neuro-Rescuing
Rescues neurons already committed to programmed cell death, effective even 3–6 hours after toxic insult and as late as 21 days postnatal in the rd10 model. Validated across multiple preclinical neuronal and animal models, with efficacy demonstrated in human iPSC-derived neurons, a critical translational signal.
Neuroprotective
The only compound with published evidence protecting neurons against all five major neurotoxic proteins: amyloid-β (Alzheimer's), α-synuclein (Parkinson's), tau, prion protein, and amylin.
Neurotrophic
Drives neurite outgrowth to restore neuronal connectivity. Higher efficacy demonstrated in human iPSC-derived neurons than in mouse neurons, a critical translational signal.
The two approved Alzheimer's drugs require biweekly IV infusions with regular MRI monitoring, and cause ARIA brain abnormalities in 13–31% of patients. SBC003 is a daily oral pill. It crosses the blood-brain and blood-retinal barriers with no structural moieties of toxic concern.
The Paradigm Is Broken. The Playbook Exists.
“The two approved Alzheimer's drugs target a single protein, require biweekly IV infusions with regular MRI monitoring, and cause ARIA brain abnormalities in 13–31% of patients — for a disease driven by at least five distinct neurotoxic proteins. One target. A five-protein disease.”
The industry's structural mistake
|99.6% trial failure rate · $42.5B wasted · 2002–2021
SBC003 vs current standard of care
The neurodegenerative drug development paradigm pursues one target per drug in one disease at a time, neglecting the underlying connection: the decay of neurons. SBC003's neuroglobin-induction mechanism protects against all five major neurotoxic proteins through a single endogenous pathway. Platform biotechs command a 30% valuation premium over single-asset companies. SBC003's expansion path: from RP (orphan, 7-year exclusivity) through dry AMD ($18B) into CNS neurodegeneration ($70B+ by 2034), follows the exact playbook that multiple peer biotech case studies have already validated.
Failure, differentiation & platform precedent
SunRegen is advancing toward Series A. We invite rigorous inquiry from institutional investors and strategic partners.
For Investors
Targeting $35M+ to fund Phase I/II clinical trials in Retinitis Pigmentosa.
For Partners
We welcome partnerships in research and clinical development across our portfolio of targeted therapeutics.
Pioneering first-in-class orally bioavailable lipid therapeutics to halt neurodegeneration and restore vision. Clinical-stage. Basel, Switzerland.
© 2026 SunRegen Healthcare AG. All rights reserved.
Business Parc Reinach, Christoph Merian-Ring 11, 4153 Reinach, Switzerland
UID: CHE-295.245.274
This website contains forward-looking statements regarding future products, development plans, and business strategies. Actual results may differ materially. Nothing on this site constitutes medical or investment advice.